Also a non-trivial question is how they did the randomization. If sutdy arm patients came from India and control-arm patients from elsewhere, the ORR difference shown would be boosted according to the data we looked at when we wrote this company up June 2010.
Randomization cures a lot of ills in Phase II trial designs for oncology products, but randomization doesn't automatically relieve investors of their job of being skeptics.
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr